TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34411199

Group type: EXPERIMENTAL
Intervention: Mouthwash and nose rinse with ARGOVIT® silver nanoparticles (AgNPs) solution
Number of subjects: 231

Group type: COMPARATOR
Intervention: Conventional mouthwash and nose rinse
Number of subjects: 231
Study: 35172727

Group type: EXPERIMENTAL
Intervention: S-ketamine (0.5 mg/kg) + sufentanil (2 μg/kg) + tropisetron (10 mg)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Control group (sufentanil 2 μg/kg + tropisetron 10 mg)
Number of subjects: 275
Study: 33340432

Group type: EXPERIMENTAL
Intervention: 1 g eicosapentaenoic acid (EPA) plus 1 g docosahexaenoic acid (DHA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 32664057

Group type: EXPERIMENTAL
Intervention: High-dissolution turmeric-sesame formulation (Rhuleave-K; 1,000 mg/d)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Acetaminophen (1,000 mg/d)
Number of subjects: 88
Study: 34076386

Group type: EXPERIMENTAL
Intervention: Sarecycline
Number of subjects: 0
Study: 32931029

Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab (arm B, AC→T→H)
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Adjuvant doxorubicin, cyclophosphamide, paclitaxel (arm A, AC→T)
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin, cyclophosphamide, paclitaxel, and trastuzumab (arm C, AC→T+H→H)
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Estrogen receptor-positive patients
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Estrogen receptor-negative patients
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Local treatment L+RT
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Local treatment M+RT
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Local treatment M
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: 1 to 3 positive lymph nodes L+RT
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: 1 to 3 positive lymph nodes M+RT
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: 1 to 3 positive lymph nodes M
Number of subjects: 2763
Study: 36399712

Group type: EXPERIMENTAL
Intervention: 70 mg leniolisib twice daily for 12 weeks
Number of subjects: 31
Study: 34358832

Group type: EXPERIMENTAL
Intervention: HMB (3 g/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 30
Study: 35168957

Group type: EXPERIMENTAL
Intervention: Digital home exercise (DHE)
Number of subjects: 763

Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 763
Study: 34596103

Group type: EXPERIMENTAL
Intervention: Da Vinci robot‐assisted radical gastrectomy (observation group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Open radical gastrectomy (control group)
Number of subjects: 98
Study: 32729784

Group type: EXPERIMENTAL
Intervention: 30 g/d glutamine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 36027560

Group type: EXPERIMENTAL
Intervention: Screening for subclinical cardiovascular disease
Number of subjects: 16736

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 16736

Group type: EXPERIMENTAL
Intervention: Screening for stroke
Number of subjects: 16736

Group type: EXPERIMENTAL
Intervention: Screening for myocardial infarction
Number of subjects: 16736

Group type: EXPERIMENTAL
Intervention: Screening for aortic dissection
Number of subjects: 16736

Group type: EXPERIMENTAL
Intervention: Screening for aortic rupture
Number of subjects: 16736
Study: 34547030

Group type: EXPERIMENTAL
Intervention: mHealth‐enabled hierarchical diabetes management intervention
Number of subjects: 19601

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 19601
Study: 34753535

Group type: EXPERIMENTAL
Intervention: EDS-FLU 186 µg
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: EDS-FLU 372 µg
Number of subjects: 482

Group type: COMPARATOR
Intervention: EDS-placebo
Number of subjects: 482
Study: 34039056

Group type: EXPERIMENTAL
Intervention: Early intubation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Late intubation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Simulated cough occurrence
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Failed first attempt laryngoscopy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intubation time
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Incidence of failed first attempt laryngoscopy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Heart rate variability
Number of subjects: 20
Study: 35404109

Group type: EXPERIMENTAL
Intervention: Laparoscopic Partial Nephrectomy (LPN)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Open Partial Nephrectomy (OPN)
Number of subjects: 208
Study: 34254272

Group type: EXPERIMENTAL
Intervention: Nasogastric (NG) feeding
Number of subjects: 77

Group type: COMPARATOR
Intervention: Nasojejunal (NJ) feeding
Number of subjects: 77
Study: 32588060

Group type: COMPARATOR
Intervention: Provisional stenting
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Two-stent technique
Number of subjects: 653
Study: 33432836

Group type: EXPERIMENTAL
Intervention: Health care content
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Racial discrimination content
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Health-related racial discrimination stories
Number of subjects: 410

Group type: COMPARATOR
Intervention: Non-health, nonracial discrimination stories
Number of subjects: 410
Study: 33852195

Group type: EXPERIMENTAL
Intervention: Ketone ester (KE) ingestion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isocaloric glucose (GLU) administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PBO) vehicle
Number of subjects: 10
Study: 32221596

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 18244
Study: 36416321

Group type: EXPERIMENTAL
Intervention: WaveOne
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1#P drill+WaveOne
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ultrasound P5 working end ET25+ProTaper Universal
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 90
Study: 34431398

Group type: EXPERIMENTAL
Intervention: Virtual reality (10 minutes)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Guided imagery (10 minutes)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Virtual reality vs. Guided imagery
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 88
Study: 32482361

Group type: EXPERIMENTAL
Intervention: Airtraq (channeled videolaryngoscope)
Number of subjects: 80

Group type: COMPARATOR
Intervention: ILMA (Intubating Laryngeal Mask Airway)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 80

Group type: COMPARATOR
Intervention: ILMA
Number of subjects: 80
Study: 36156543

Group type: EXPERIMENTAL
Intervention: Functional training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 14
Study: 34597955

Group type: EXPERIMENTAL
Intervention: NOL-guided fentanyl administration
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standardization of care (SOC)
Number of subjects: 70
Study: 34253409

Group type: EXPERIMENTAL
Intervention: Combination of treatments including education, orthosis, hand exercises, and topical anti-inflammatory gel
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Baseline function
Number of subjects: 94
Study: 32434495

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 16

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 16
Study: 36054756

Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg/day (PACE)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg/day (OPTIC)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Ponatinib 15 mg/day (OPTIC, response-based dosing)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Serious treatment-emergent adverse events (PACE)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Serious treatment-emergent adverse events (OPTIC)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Serious treatment-emergent arterial occlusive events (PACE)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Serious treatment-emergent arterial occlusive events (OPTIC)
Number of subjects: 350
Study: 33291045

Group type: EXPERIMENTAL
Intervention: Multisensory integration (MSI) in autistic individuals
Number of subjects: 156

Group type: COMPARATOR
Intervention: Multisensory integration (MSI) in neurotypical individuals
Number of subjects: 156
Study: 32468508

Group type: EXPERIMENTAL
Intervention: Infusion of hyperimmune plasma from convalescent donors of COVID-19
Number of subjects: 43
Study: 35696383

Group type: EXPERIMENTAL
Intervention: Books by Black authors
Number of subjects: 9072

Group type: COMPARATOR
Intervention: Books by female authors
Number of subjects: 9072

Group type: COMPARATOR
Intervention: Books by young authors
Number of subjects: 9072
Study: 33090208

Group type: EXPERIMENTAL
Intervention: 100 mg of oral DMAU for 28 days
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 200 mg of oral DMAU for 28 days
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 400 mg of oral DMAU for 28 days
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 81
Study: 35831797

Group type: EXPERIMENTAL
Intervention: TXA retrograde injection (TXA-RI)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: TXA-soaked absorbable Gelfoam (TXA-Gel)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 133
Study: 33602374

Group type: EXPERIMENTAL
Intervention: Exercise and nutrition supplementation
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Condiments (42.4%), cereals and their products (16.8%), soups (13.5%)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Higher intakes of seafood and nuts
Number of subjects: 114
Study: 35252940

Group type: EXPERIMENTAL
Intervention: Higher concentrations of testosterone (quartile 4)
Number of subjects: 5535

Group type: EXPERIMENTAL
Intervention: Higher concentrations of DHEA (quartile 4)
Number of subjects: 5535

Group type: EXPERIMENTAL
Intervention: Higher concentrations of oestrone (quartile 2)
Number of subjects: 5535

Group type: EXPERIMENTAL
Intervention: SHBG
Number of subjects: 5535

Group type: EXPERIMENTAL
Intervention: Any hormone or SHBG
Number of subjects: 5535
Study: 32000723

Group type: EXPERIMENTAL
Intervention: PTSD Checklist‐Civilian Version used for screening PTSD
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Demographic risk factors (gender, income, age at loss, medical conditions, duration of being Shidu)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Regression analysis
Number of subjects: 149
Study: 33739127

Group type: EXPERIMENTAL
Intervention: 3-month aspirin therapy with continued ticagrelor
Number of subjects: 2660

Group type: COMPARATOR
Intervention: 12-month aspirin and ticagrelor
Number of subjects: 2660
Study: 32619458

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no stressor)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Changes in PEP and HF
Number of subjects: 85
Study: 36436387

Group type: EXPERIMENTAL
Intervention: Physical and cognitive training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical training alone
Number of subjects: 0
Study: 33333430

Group type: EXPERIMENTAL
Intervention: Treatment adherence programme (TAP)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 151
Study: 33181658

Group type: EXPERIMENTAL
Intervention: Locking plate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramedullary nail
Number of subjects: 0
Study: 35343369

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham Kinesio taping
Number of subjects: 66
Study: 33413273

Group type: EXPERIMENTAL
Intervention: Baseline characteristics including younger age, higher body mass index (BMI), greater WOMAC pain scores, dysfunction scores, stiffness scores, lower education level, more than one comorbidity, and two or more painful body sites
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Higher WOMAC pain and dysfunction scores at baseline
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Baseline depression
Number of subjects: 397
Study: 32768569

Group type: EXPERIMENTAL
Intervention: Conservative oxygen therapy
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Septic subgroup (both interventions)
Number of subjects: 125
Study: 35441464

Group type: EXPERIMENTAL
Intervention: Opioid analgesic prescription at hospital discharge
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Opioid analgesic use 4 weeks after ED presentation
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Predictors of continued opioid use
Number of subjects: 104
Study: 34585874

Group type: EXPERIMENTAL
Intervention: SRP+AV
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: SRP+PDT
Number of subjects: 150

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 150
Study: 32781905

Group type: EXPERIMENTAL
Intervention: Induced pluripotent stem cell-derived megakaryocyte clones with gene knockdown of GP-5, GRN, and MPO
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Protein-PLT/MPV association analysis
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: RNA-sequencing analysis
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Genome-wide association study
Number of subjects: 71
Study: 36589612

Group type: EXPERIMENTAL
Intervention: Supervised aerobic plus stretching (Group 1)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Supervised resistance plus stretching (Group 2)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Home-based stretching (Group 3)
Number of subjects: 41
Study: 32747494

Group type: EXPERIMENTAL
Intervention: Valve replacement (surgical or percutaneous)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural history observation
Number of subjects: 0
Study: 34020962

Group type: EXPERIMENTAL
Intervention: Methylphenidate (10 mg two times per day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (identical capsules two times per day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups (Methylphenidate and Placebo)
Number of subjects: 23
Study: 32990610

Group type: EXPERIMENTAL
Intervention: Konjac powder beverage 30 minutes before each meal
Number of subjects: 76

Group type: COMPARATOR
Intervention: Resistant maltodextrin beverage
Number of subjects: 76
Study: 34882907

Group type: EXPERIMENTAL
Intervention: Intervention A - written aphasia-friendly information provision
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intervention B - collaborative goal-setting
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Targeted behaviour change domains
Number of subjects: 35
Study: 33430735

Group type: EXPERIMENTAL
Intervention: Pidotimod supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (without Pidotimod supplementation)
Number of subjects: 40
Study: 33138838

Group type: EXPERIMENTAL
Intervention: OsteoMaster
Number of subjects: 67

Group type: COMPARATOR
Intervention: Miniaci
Number of subjects: 67
Study: 35202193

Group type: EXPERIMENTAL
Intervention: Evofosfamide (Evo) + Doxorubicin (Dox)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Doxorubicin (Dox)
Number of subjects: 296
Study: 33744193

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 85

Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 85
Study: 35217226

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 50

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: No strong preference for anesthesia techniques
Number of subjects: 50

Group type: COMPARATOR
Intervention: Strong preference for anesthesia techniques
Number of subjects: 50
Study: 33982941

Group type: EXPERIMENTAL
Intervention: STRIVE (30-minute strength training video plus health coach)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 83
Study: 35661954

Group type: EXPERIMENTAL
Intervention: Locoregional therapy (LRT) for the primary site of breast cancer
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (no locoregional therapy)
Number of subjects: 4
Study: 33406234

Group type: EXPERIMENTAL
Intervention: SHORT inter‐set rest interval (one‐minute)
Number of subjects: 10

Group type: COMPARATOR
Intervention: LONG inter‐set rest interval (three‐minute)
Number of subjects: 10
Study: 32738479

Group type: EXPERIMENTAL
Intervention: 7.5-μg vaccine
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 15-μg vaccine
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 30-μg vaccine
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 35457633

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 24)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 41
Study: 32397596

Group type: EXPERIMENTAL
Intervention: Training session (RH group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Match (RH group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Training session (comparison between NH and RH groups)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Match (comparison between NH and RH groups)
Number of subjects: 28
Study: 36412015

Group type: EXPERIMENTAL
Intervention: Yeahhh Baby!® ointment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 32423561

Group type: EXPERIMENTAL
Intervention: Supraflex stent (sirolimus-eluting, ultrathin strut)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Xience stent (everolimus-eluting, thicker strut)
Number of subjects: 0
Study: 33373715

Group type: EXPERIMENTAL
Intervention: Visual acuity at month 01 (M01)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Central subfield thickness (CST) at month 01 (M01)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Subretinal fluid at month 01 (M01)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Intraretinal fluid at month 01 (M01)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Disorganization of retinal inner layers (DRIL) at month 01 (M01)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Ellipsoid zone (EZ) at month 01 (M01)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Visual acuity at month 06 (M06)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Visual acuity at month 12 (M12)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Visual acuity at month 24 (M24)
Number of subjects: 362
Study: 33573421

Group type: EXPERIMENTAL
Intervention: Local pain (Capsaicin gel applied)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Remote pain (Capsaicin gel applied)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups (including local and remote pain)
Number of subjects: 90
Study: 33684624

Group type: EXPERIMENTAL
Intervention: 1 oral dose of 50 mg of naltrexone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20
Study: 32907896

Group type: EXPERIMENTAL
Intervention: Active Monitoring (AM): 3-monthly serum prostate-specific antigen (PSA) assessment in year 1, 6-12 monthly thereafter; review triggered by increase in PSA ≥50% during previous 12 months or patient/clinician concern.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active Monitoring (AM)
Number of subjects: 20
Study: 35271958

Group type: EXPERIMENTAL
Intervention: Concentric circle method, 3 mL
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Concentric circle method, 10 mL
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Back-and-forth friction method, 3 mL
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Back-and-forth friction method, 10 mL
Number of subjects: 32

Group type: COMPARATOR
Intervention: Back-and-forth friction methods (C and D) vs. concentric circles (A and B)
Number of subjects: 32
Study: 34422279

Group type: EXPERIMENTAL
Intervention: Contraception Choices online trial
Number of subjects: 18
Study: 33330119

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 N-protein test strip
Number of subjects: 0
Study: 35926996

Group type: EXPERIMENTAL
Intervention: F@ce 2.0 intervention
Number of subjects: 160
Study: 33454970

Group type: EXPERIMENTAL
Intervention: SCSH before endometrial aspiration
Number of subjects: 232

Group type: COMPARATOR
Intervention: Endometrial aspiration before SCSH
Number of subjects: 232
Study: 32616489

Group type: EXPERIMENTAL
Intervention: Impryl (nutritional supplement), one tablet each day for a total duration of 6 months
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo, one tablet each day for a total duration of 6 months
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Impryl (nutritional supplement)
Number of subjects: 1200
Study: 35802374

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy
Number of subjects: 321

Group type: COMPARATOR
Intervention: Exercise-based physical therapy
Number of subjects: 321

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 321
Study: 33967176

Group type: EXPERIMENTAL
Intervention: Unilateral VIM-FUS thalamotomy
Number of subjects: 11
Study: 32336038

Group type: EXPERIMENTAL
Intervention: Lenabasum (5 mg once daily, 20 mg once daily, or 20 mg twice daily for 4 weeks, followed by 20 mg twice daily for 8 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 34699396

Group type: COMPARATOR
Intervention: AC-CROS
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: aBC-CROS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unaided
Number of subjects: 10
Study: 33866860

Group type: EXPERIMENTAL
Intervention: BRAVE intervention (system provider level training intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control CMH teams
Number of subjects: 0
Study: 32729217

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 3304

Group type: COMPARATOR
Intervention: First-generation standard-of-care basal insulin analogues (SOC‐BI; insulin glargine 100 U/mL or insulin detemir)
Number of subjects: 3304